====== Beate Sander ======

{{ ::08_small-180x180.jpeg?150|}}

Dr. **Beate Sander**, RN, MBA, MEcDec, PhD, is a Canadian infectious disease economist based in Toronto, Ontario, with expertise in health economics and simulation modeling. She is notable in the [[COVID-19 pandemic]] due to her role on the [[Ontario COVID-19 Science Advisory Table]].

She contributes substantively to federal/provincial policy decision-making, serving as an expert to national and international advisory bodies.

===== Education =====

Sander has studied at several institutions internationally:((//Beate Sander.// Institute of Health Policy, Management and Evaluation; University of Toronto. Retrieved March 10, 2022, from https://ihpme.utoronto.ca/faculty/beate-sander/))

  * PhD ([[University of Toronto]])
  * MEcDev ([[Australian National University]], Australia)
  * MBA ([[Technische Universität Bergakademie Freiberg]], Germany)
  * RN ([[Medizinische Fachschule Chemnitz]], Germany)

===== Affiliations =====

==== University of Toronto ====

Beate is an Associate Professor at the Institute of Health Policy, Management and Evaluation at the [[University of Toronto]].((//Beate Sander.// Institute of Health Policy, Management and Evaluation; University of Toronto. Retrieved March 10, 2022, from https://ihpme.utoronto.ca/faculty/beate-sander/))

==== University Health Network ====

Sander is the Director of Population Health Economics Research (PHER) at the [[toronto_general_hospital:Toronto General Hospital Research Institute]] under [[University Health Network]].((//Beate Sander.// UHN Research. Retrieved March 10, 2022, from https://www.uhnresearch.ca/researcher/beate-sander))

==== National Advisory Committee on Immunization ====

Sander is a member of the [[National Advisory Committee on Immunization]] (NACI), where she also chairs the Economics Task Group and co-chairs the Economic Guidelines Task Group. She receives reimbursement to attend NACI meetings, and acknowledges this role presents a conflict of interest with her work on the OST (including regarding [[COVID-19 vaccines]]).((Sander, B. (2020). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220108230014/https://covid19-sciencetable.ca/wp-content/uploads/2020/07/Declaration-of-Interest_Science-Table_Beate-Sander.pdf))
==== Society for Medical Decision Making ====

Sander is an active member of the [[Society for Medical Decision Making]] (SMDM), where she was elected as President.((//SMDM 2021 - 22 Officers & Trustees Election Results.// (2021). Society for Medical Decision Making. https://archive.ph/O2hul)) She had served as Vice President in 2017-2018.((//Introducing the SMDM 2017 - 2018 Officers and Trustees.// Society for Medical Decision Making. Retrieved March 10, 2022, from https://archive.ph/bElb9)) She participated in a December 26, 2020 webinar in which she delivered a talk titled "Ensemble Modelling to Inform COVID-19 Policy Response".((Society For Medical Decision Making. (2020, December 6). //Lessons to Serve a Growing Purpose of Economic Evaluation in the U.S. in the 2020s.// YouTube. https://web.archive.org/web/20220310235022/https://www.youtube.com/watch?v=9mFqVJEOBgg)) ((//Distance Learning Educational Events.// Society for Medical Decision Making. Retrieved March 10, 2022, from https://archive.ph/L2MfT))

She is also on the editorial board of the Medical Decision Making journal.((//Editorial Board.// SAGE Journals. Retrieved March 10, 2022, from https://archive.ph/D4s0q))
==== Public Health Ontario ====

Sander is a scientist in Communicable Diseases, Emergency Preparedness and Response at [[public_health_agencies:canada:Public Health Ontario]].((//Beate Sander - Biography.// Institute for Clinical Evaluative Sciences (ICES). Retrieved March 10, 2022, from https://archive.ph/KaSTz))

==== Canadian Centre for Health Economics ====

Sander is a Faculty Associate at the [[university_of_toronto:Canadian Centre for Health Economics]] (CCHE).((//Associates.// Canadian Centre for Health Economics - Centre Canadien En Economie de La Santé. Retrieved March 10, 2022, from https://www.canadiancentreforhealtheconomics.ca/about/associates/))

==== THETA Collaborative ====

Sander is a Scientist and the Director of Population Health Economics Research at [[Toronto Health Economics and Technology Assessment Collaborative]] (THETA), associated with the [[Toronto General Hospital:Toronto General Hospital Research Institute]].((//Beate Sander.// Institute for Clinical Evaluative Sciences (ICES). Retrieved March 10, 2022, from https://archive.ph/uPGNw))

==== Canadian Lyme Disease Research Network ====

Sander is a Scientific Co-Chair of the [[Canadian Lyme Disease Research Network]], a project lead by [[public_health_agencies:canada:public_health_ontario:Kieran Moore]], Chief Medical Officer of Health (CMOH) for [[public_health_agencies:Public Health Ontario]].((//Meet The Team.// Canadian Lyme Disease Research Network. Retrieved March 10, 2022, from https://archive.ph/KNI39)) The project is funded through the [[Canadian Institute for Health Information]] (CIHI), and Sander is a co-applicant on the grant.((Moore, K. (2019, July 29). //Disclosure of Conflict of Interest.// Canadian Lyme Disease Research Network. Retrieved November 24, 2021, from https://www.clydrn.ca/wp-content/uploads/2019/07/Moore-Kieran.pdf)) ((Canadian Lyme Disease Research Network. //Kieran Moore Bio.// Retrieved November 24, 2021, from https://www.clydrn.ca/the-team-kieran-moore/)) She reported no conflicts of interest in a July 9, 2019 disclosure.((Sander, B. (2019). //Disclosure of Conflict of Interest Definitions.// Canadian Lyme Disease Research Network. https://web.archive.org/web/20210509002642/https://www.clydrn.ca/wp-content/uploads/2019/07/Sander-Beate.pdf))

==== York University ====

Sander is an Adjunct Faculty member in the Department of Mathematics and Statistics at [[York University]], and a member of the [[LAboratory of Mathematical Parallel Systems]] laboratory.((//Members of LAMPS.// LAboratory of Mathematical Parallel Systems. Retrieved March 11, 2022, from https://archive.ph/hWNyW)) ((//Beate Sander.// UHN Research. Retrieved March 10, 2022, from https://www.uhnresearch.ca/researcher/beate-sander))
==== Institute for Clinical Evaluative Sciences (2012-current) ====

In 2012, Sander joined as an Adjunct Scientist at the [[Institute for Clinical Evaluative Sciences]] (ICES).((//Beate Sander.// Institute for Clinical Evaluative Sciences (ICES). Retrieved March 10, 2022, from https://archive.ph/uPGNw))

==== Canadian Institutes of Health Research (2019-present) ====

On April 1, 2019, Sander became the Canada Research Chair in Economics of Infectious Diseases, affiliated with the [[Canadian Institutes of Health Research]] (CIHR) and the [[University of Toronto]].((//Beate Sander.// (2021, June 25). Canada Research Chairs. https://archive.ph/HUfd4)) She is principal investigator of several multidisciplinary projects funded by CIHR and other funders, including an evaluation of [[Zika]] virus and [[COVID-19]] interventions using computer simulation.

The CIHR has awarded Sander the following grants:

  * 2014-2018: $475,367.00 as co-primary investigator for "Reducing the burden of hospital-associated Clostridium Difficile infections in Canada through optimal prevention policies: A multidisciplinary individual-based modeling approach"((//Beate Sander.// Institute of Health Policy, Management and Evaluation; University of Toronto. Retrieved March 10, 2022, from https://ihpme.utoronto.ca/faculty/beate-sander/))
  * 2014-2017: $450,000.00 as PI for "The cost-effectiveness of West Nile virus intervention strategies. A computer simulation model."
  * 2014-2015: $99,000.00 as PI for "Assessing the health and economic burden of Lyme disease using laboratory and health administrative data." One collaborator is [[Samir Patel]], a co-OST member and Chief of Microbiology at [[public_health_agencies:Public Health Ontario]].
  * 2014: $15,000.00 as co-PI for "The Cost-Effectiveness of Integrated Cervical Cancer Prevention Strategies in Ontario."
  * 2013-2016: $474,627.00 as PI for "Estimating longitudinal healthcare cost for infectious diseases using administrative data."
  * 2013-2015: $45,000.00 as PI for "Assessing the health and economic burden of mycobacterial infections using laboratory and health administrative data."

==== Ontario COVID-19 Science Advisory Table (2020-present) ====

Sander is a member of the [[Ontario COVID-19 Science Advisory Table]].((//About Us.// Ontario COVID-19 Science Advisory Table. Retrieved March 10, 2022, from https://covid19-sciencetable.ca/about/#sander-beate))

===== Research =====

Sander's research is focused on "developing economic strategies to evaluate interventions to combat infectious and vector-borne diseases." She and her team "are addressing challenges in the use of costing data in economic evaluations, the need for disease-specific and comprehensive simulation models, and the broader societal impact of infectious diseases and their interventions."((//Beate Sander.// (2021, June 25). Canada Research Chairs. https://archive.ph/HUfd4))

Additional areas of interest include "Economic evaluation of health care interventions with a focus on [[public health]], decision analysis, health economics, mathematical modeling, use of laboratory, surveillance, and administrative data for economic evaluation, public health, [[vaccines|vaccine]]-preventable diseases".((//Beate Sander.// Institute of Health Policy, Management and Evaluation; University of Toronto. Retrieved March 10, 2022, from https://ihpme.utoronto.ca/faculty/beate-sander/))

==== Vaccines ====

  * Sander led a 2010 study titled "The Cost-Effectiveness of Ontario’s Universal Influenza Immunization Program", which she credits as "the first study to provide evidence that a universal program is economically attractive in jurisdictions with influenza epidemiology and health care costs broadly similar to Ontario."((Sander, B., Kwong, J. C., Bauch, C. T., Maetzel, A., McGeer, A., Raboud, J. M., & Krahn, M. (2010). //Economic Appraisal of Ontario’s Universal Influenza Immunization Program: A Cost-Utility Analysis.// PLoS Medicine, 7(4), e1000256. https://doi.org/10.1371/journal.pmed.1000256)) The study contributed to the implementation of public health policies around universal flu vaccination in Canada and the United States. Her co-authors include fellow OST member [[Allison McGeer]].
    * Funded by the [[Institute for Clinical Evaluative Sciences]] (ICES), [[Public Health Agency of Canada]], and the [[University of Toronto]].
  * She also co-authored "Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience" alongside [[Allison McGeer]] and [[David Fisman]], current and former OST comrades. The study concluded that "Ontario’s pandemic H1N1 immunization program was cost-effective as implemented".((Sander, B., Bauch, C. T., Fisman, D., Fowler, R. A., Kwong, J. C., Maetzel, A., McGeer, A., Raboud, J., Scales, D. C., Gojovic, M. Z., & Krahn, M. (2010). //Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.// Vaccine, 28(38), 6210–6220. https://doi.org/10.1016/j.vaccine.2010.07.010)) 
    * Funded by the [[Canadian Institutes of Health Research]] (CIHR).
  * //The benefits of pneumococcal vaccination for seniors: a Centre for Vaccine Preventable Diseases interdisciplinary project on healthy aging and immunization science//((//Beate Sander.// Institute for Clinical Evaluative Sciences (ICES). Retrieved March 10, 2022, from https://archive.ph/uPGNw))
    * Funded through ICES by the [[Connaught Fund]] for a total of $248,789.00.
  * //The epidemiology and economic burden of hepatitis C viral infection in the First Nations population in Ontario//
    * Funded through ICES by the [[Canadian Institutes of Health Research]] for a total of $650,250.00.
  * //The prevention of group B streptococcal (GBS) disease in infants//
    * Funded through ICES by the [[Canadian Institutes of Health Research]] for a total of $409,276.00.

She has also received funding from the [[Canadian Immunization Research Network]], [[Ontario Health]], the [[public_health_agencies:Canada:Public Health Agency of Canada]] and the [[World Health Organization]].((Sander, B. (2020). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220108230014/https://covid19-sciencetable.ca/wp-content/uploads/2020/07/Declaration-of-Interest_Science-Table_Beate-Sander.pdf)) ((Sander, B. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://web.archive.org/web/20220309073247/https://covid19-sciencetable.ca/wp-content/uploads/2020/07/Declaration-of-Interest_Science-Table_Beate-Sander-1.pdf))
==== COVID-19 ====

Beate received funding from the Ontario COVID-19 Rapid Research Fund as principal investigator for an "Ontario Together" study titled "Ontario’s Response to COVID-19: Balancing Trade-offs and Improving Outcomes for all Ontarians".((//Ontario COVID-19 Rapid Research Fund.// Government of Ontario. Retrieved March 10, 2022, from https://archive.ph/I2enS))

The CIHR provided her a grant as Co-Investigator for "Scalable, Customizable, Digital Health Communication Materials to Help Canada Address the COVID-19 Pandemic" at Witteman Lab.((Parent, E. //Scalable, Customizable, Digital Health Communication Materials to Help Canada Address the COVID19 Pandemic.// Witteman Lab. Retrieved March 10, 2022, from https://archive.ph/pVPDW))

Beate received a grant from the [[Canadian Cardiovascular Society]]'s COVID-19 Challenge for Canada Initiative for a study titled "Co-Investigator Consequences of delays in cardiac procedures and surgeries due to the COVID-19 pandemic". Additional funding came from the [[Heart and Stroke Foundation of Canada]] and ICES.((Tam, D. Y., Qiu, F., Manoragavan, R., Fremes, S. E., Hassan, A., Ko, D. T., Lauck, S. B., Naimark, D., Ouzounian, M., Sander, B., Sun, L., & Wijeysundera, H. C. (2021). //The Impact of the COVID-19 Pandemic on Cardiac Procedure Wait List Mortality in Ontario, Canada.// Canadian Journal of Cardiology, 37(10), 1547–1554. https://doi.org/10.1016/j.cjca.2021.05.008))
===== Awards and Recognition =====

  * Thomas and Edna Naylor Memorial Award, 2012((//Beate Sander.// Institute of Health Policy, Management and Evaluation; University of Toronto. Retrieved March 10, 2022, from https://ihpme.utoronto.ca/faculty/beate-sander/))
    * $1,000 award presented for best paper "Thesis in Health Services and Health Care Research"
  * Lee B. Lusted Student Prize, 2010 for outstanding presentation of research. 
    * $500.00 awarded to Society for Medical Decision Making (SMDM) at the 31th Annual Meeting, Toronto, ON, Canada

===== Relationships with Pharmaceutical Companies =====

Sander received unrestricted funding to serve as a consultant to [[pharmaceutical_companies:Roche]] for work on [[pharmaceutical_products:Tamiflu]], as well as travel grants and honoraria for speaking at meetings on pandemic influenza mitigation strategies.((Sander, B., Kwong, J. C., Bauch, C. T., Maetzel, A., McGeer, A., Raboud, J. M., & Krahn, M. (2010). //Economic Appraisal of Ontario’s Universal Influenza Immunization Program: A Cost-Utility Analysis.// PLoS Medicine, 7(4), e1000256. https://doi.org/10.1371/journal.pmed.1000256))

She also received a $2,500.00 award from [[pharmaceutical_companies:Sanofi]] for Communicable Disease Epidemiology.((//Beate Sander.// Institute of Health Policy, Management and Evaluation; University of Toronto. Retrieved March 10, 2022, from https://ihpme.utoronto.ca/faculty/beate-sander/))

===== Media =====

Sander was interviewed in December 2021 for the [[Toronto Star]] on the subject of the [[sars-cov-2:Omicron]] variant.((Arthur, B. (2021, December 10). //Opinion | It’s hard to look this in the eye. But COVID’s worst is coming.// The Toronto Star. https://archive.ph/nHfPM))